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Highlights  
 
• Partial loss of heme oxygenase-1 under high soluble Flt-1 (sFlt-1) environment 
gives rise to far severe preeclampsia compared to high sFlt-1 alone 
• Hydrogen sulfide releasing aspirin, MZe786 suppresses hypertension, kidney injury 
and poor fetal outcome and improves antioxidant defense 
• MZe786 is able to rescue pregnancy despite the persistent high levels of sFlt-1  
• MZe786 is a superior therapeutic candidate than aspirin in preventing preeclampsia 
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Abstract 
Preeclampsia affects one in twelve of the 130 million pregnancies a year. The lack of an 
effective therapeutic to prevent or treat it is responsible for an annual global cost burden of 
100 billion US dollars. Preeclampsia also affects these women later in life as it is a 
recognised risk factor for cardiovascular disease, stroke and vascular dementia. Our 
laboratory demonstrated that preeclampsia is associated with high soluble fms-like 
tyrosine kinase 1 (sFlt-1) and low heme oxygenase-1 (HO1 / Hmox1) expression.  Here we 
sought to determine the therapeutic value of a novel H2S-releasing aspirin (MZe786) in 
HO-1 haploid deficient (Hmox1+/-) pregnant mice in a high sFlt-1 environment. Pregnant 
Hmox1+/- mice were injected with adenovirus (Ad) encoding sFlt-1 or CMV (control virus) 
at gestation day E11.5. Subsequently, Hmox1+/- dams were treated daily with a number of 
treatment regimens until E17.5, when maternal and fetal outcomes were assessed. Here 
we show that HO-1 compromised mice in a high sFlt-1 environment during pregnancy 
exhibit severe preeclampsia signs and a reduction in antioxidant genes. MZe786 
ameliorates preeclampsia by reducing hypertension and renal damage possibly by 
stimulating antioxidant genes. MZe786 also improved fetal outcome in comparison with 
aspirin alone and appears to be a better therapeutic agent at preventing preeclampsia 
than aspirin alone.  
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Introduction 
Preeclampsia is a systemic disorder of pregnancy, affecting over 10 million women and 
annually accounts for over 76,000 maternal deaths and 500,000 infant deaths (1-3). This 
equates to a life lost every minute. Clinically, preeclampsia manifests itself as de novo 
onset of hypertension during pregnancy along with one or more of the complications 
affecting heart, lungs, kidney, liver and feto-placental systems. Importantly, women who 
have experienced preeclampsia are three to four times more at risk of developing high 
blood pressure later in life; twice as likely to develop heart disease, heart failure, stroke (4-
6) and they are three times more likely to develop vascular dementia later in life (7). There 
are no effective pharmacological agents to prevent or treat preeclampsia. In women at 
high risk of developing preeclampsia, aspirin appears to reduce the risk of preeclampsia 
by 15% if taken from 12 weeks of pregnancy (8). The only solution to protect the life of the 
mother is the delivery of the baby with the placenta. However, induced preterm birth 
jeopardises the life and health of the infant both in the short-term and long-term (9). 
Several studies have validated the hypothesis that preeclampsia arises due to ‘increase in 
the level of endogenous soluble Flt-1 (sFlt-1) that may antagonize the beneficial effects of 
vascular endothelial growth factor (VEGF)’(10-13). Rodents treated with adenovirus 
encoding sFlt-1 develop preeclampsia-like phenotype with high blood pressure and kidney 
damage (12, 14). The most prominent factor linked to the pathogenesis of preeclampsia is 
the elevated level of sFlt-1 (15). Although high maternal sFlt-1 is unique to preeclampsia, 
not all women with high sFlt-1 develop preeclampsia (16).  
Human heme oxygenase-1 (Hmox1/HO-1) deficiency leads to severe and persistent 
endothelial damage (17), which is a hallmark of preeclampsia. The importance of HO-1 in 
preeclampsia was first highlighted when induction of HO-1 was shown to attenuate tumour 
necrosis factor alpha-induced placental damage ex vivo (18). Adenoviral overexpression of 
HO-1 inhibits sFlt-1 expression in endothelial cells (19) and HO-1 is decreased in the 
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placenta from preeclamptic women compared to healthy pregnancy (18). More recent 
studies have confirmed the significance of this protective enzyme (20). First trimester 
chorionic villous (fetal placental cells) sampling revealed a reduction in Hmox1 mRNA from 
women who subsequently went on to develop preeclampsia compared to normal 
pregnancy (21). Furthermore, a more recent study showed that that guanine-thymine 
(GTn) microsatellite in the Hmox1 promoter decreases HO-1 expression and there was an 
association between long fetal and maternal GTn repeats and lower placental and serum 
HO-1 levels indicating that partial loss of HO-1 activity may increase the risk of 
preeclampsia (22). Indeed, HO-1 expression increases by 15-folds during normal 
pregnancy and plays a crucial role in the healthy development of pregnancy (22-24).  
In women with preeclampsia, the expression of hydrogen sulfide producing enzyme, 
cystathionine gamma-lyase (CSE) is decreased in the placenta and so is the levels of 
hydrogen sulfide (H2S) in the maternal circulation (25).  Pregnant C57BI6/J mice treated 
with a CSE inhibitor, DL-Propargylglycine (PAG), developed  ‘preeclampsia phenotype’, 
characterised by hypertension, kidney damage and fetal growth restriction (FGR) (25). H2S 
is a potent promoter of vasodilatation (26), exhibits cytoprotective anti-inflammatory 
properties (27), protects against reperfusion injury (28) and stimulates angiogenesis (29). 
Therapeutic potential of H2S for its anti-inflammatory and cytoprotective properties have 
been explored through preservation of mitochondrial function and regulation of calcium 
homeostasis (30, 31).  
The current study demonstrates that partial loss of HO-1 in a high sFlt-1 environment 
leads to preeclampsia. Overexpression of sFlt-1 in HO-1 haploid deficient mice (Hmox1+/-) 
pregnant mice showed exacerbated increase in blood pressure, kidney damage, altered 
placental morphology and adverse fetal outcomes. The H2S-releasing aspirin, MZe786 
suppressed these adverse events. Finally, we demonstrated that the MZe786 is a better 
candidate at preventing preeclampsia than aspirin or H2S alone.  
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Materials and Method 
For detailed descriptions of the materials and methods used, please see Supplementary 
file. 
Materials 
The H2S-releasing molecules, MZe786 (2-acetyloxybenzoic acid 4-(3-thioxo-3H-1,2-dithiol-
5-yl)phenyl ester) and MZe486 ( 5-(4-hydroxyphenyl)-1,2-dithiol-3-thione) are shown to be 
safe and effective with a defined pharmacological profile (32).  
Methods 
Animal experimental protocol 
Pregnant mice were injected with adenovirus encoding sFlt-1 (Ad-sFlt-1) or control virus 
(Ad-CMV) (Vector Biolabs, USA) at 1x 109 plaque forming unit (PFU) via tail vein injection 
on day E11.5. The Hmox1+/- mice were separated into different treatment groups and 
treated with: (A) Drug Carrier (Control), (B) 50mg/kg ACS14, (C) 29/mg/kg ADTOH and 
(D) 23mg/kg Aspirin up to E17.5. The mice were placed in metabolic cages and urine was 
collected for 24 hours from E16.5 to E17.5, at which time, tissues were harvested. 
 
Blood pressure and ultrasound measurements 
Blood pressure was measured on E17.5 as described previously (25). In addition, 
ultrasound analysis of uterine and umbilical arteries was conducted on E17.5 (see 
Supplementary file for details). 
 
Enzyme linked immunosorbent assay 
Enzyme-linked immunosorbent assay (ELISA) kits for murine sVEGFR1/Flt-1, KIM-1, sEng 
and E-selectin were obtained from R&D Systems and performed according to the 
manufacturer’s specifications. 
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Quantitative polymerase chain reaction 
RNA was extracted from the kidneys using the RNeasy minikit (Qiagen, Germany) and 
real-time PCR was performed as previously described (33). 
 
Tissue processing and histological analysis 
Murine renal and placental tissues were stained with H&E and were imaged using 
NanoZoomer (Hamamasu, Japan). The area of the labyrinth zone was measured and 
analysed using ImageJ. The damaged glomeruli were counted and calculated. 
 
Trimethylsulfonium measurement 
Trimethylsulfonium was measured in the urine using HPLC method (see Supplementary 
file). 
 
Statistical analysis 
Data is presented as either representatives, mean and SEM or median and range as 
appropriate. Comparison between two groups was performed using Mann-Whitney U-test 
(non-parametric). Comparisons among three or more groups were performed using One-
Way or Two-Way ANOVA. Statistical analysis was performed using GraphPad Prism 8.1 
software (GraphPad Software, La Jolla, CA). Statistical significance was set at p<0.05.  
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Results 
Hmox1 deficient mice show severe preeclampsia symptoms in the presence of high 
sFlt-1.  
Maternal hypertension and kidney damage are the key clinical features of preeclampsia. 
To determine whether HO-1 haploid deficient mice (Hmox1+/-) in the presence of high sFlt-
1 cause preeclampsia-like symptoms, Hmox1+/+ and Hmox1+/- pregnant mice were injected 
with either Ad-CMV or Ad-sFlt-1 via tail vein injection on day E11.5. Ad-sFlt-1 injection 
resulted in a significantly higher mean arterial pressure (MAP) in Hmox1+/+ mice and in 
Hmox1+/- mice compared to the CMV treated counterparts. More importantly, MAP was 
significantly higher in Hmox1+/- compared to Hmox1+/+ mice following Ad-sFlt-1 injection 
(Figure 1A).  
Glomerular endotheliosis results in poor filtration and increased protein in the urine is seen 
in preeclampsia (34). HO-1 deficiency and high circulating level of sFlt-1 caused 
glomerular degeneration and narrowing or disappearance of Bowman’s space (Figure 1B). 
This was confirmed by randomized single-blind scoring of kidney sections, which showed 
significantly higher levels of glomeruli damage in mice treated with Ad-sFlt-1 both in 
Hmox1+/+ and Hmox1+/-. The glomeruli damage was further exacerbated by Ad-sFlt-1 in 
Hmox1+/- mice compared to Hmox1+/+ mice (Figure 1C).   
Poor fetal outcomes and FGR are linked to preeclampsia (35). FGR is where the fetus is 
smaller than expected at gestational age and is often described as an estimated weight 
less than the 10th percentile (36). To investigate the impact of high circulating level of sFlt-
1 on fetus, fetal loss and fetal weight were assessed. Figure 1D shows representative 
images of unhealthy-looking uterine horn and signs of fetal death (FD) by fetal 
reabsorption in Hmox1+/- pregnant mice injected with Ad-sFlt-1. Fetal loss expressed as a 
percentage increased in Hmox1+/+ Ad-sFlt-1 injected mice (17.8%) compared to Hmox1+/+ 
mice injected with Ad-CMV (9.5%). Fetal loss was further increased in Hmox1+/- mice 
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injected with Ad-sFlt-1 (46.0%) compared to Hmox1+/- mice injected with Ad-CMV (27.9%) 
(Figure 1E). In addition to fetal death, fetal weight was related to the genotype and the 
levels of sFlt-1. In the 10th percentile population, pups from Hmox1+/+ mice injected with 
Ad-CMV were 10.71% of the total population, which increased to 16.85% with Ad-sFlt-1 
injections (Supplementary Table S1). Hmox1+/+ mice also had a steeper distribution 
compared to Hmox1+/-, which was much shallower; Ad-sFlt-1 injection shifted both curves 
to the left (Figure 1F). A larger percentage of the Hmox1+/- mice pups were growth 
restricted compared to Hmox1+/+ mice (33.33% of Hmox1+/- mice injected with Ad-sFlt-1 
were growth restricted compared to 13.51% when injected with Ad-CMV, Supplementary 
Table S1). The data shows that Hmox1+/- pregnant mice under a high sFlt-1 environment 
serve as a useful model to evaluate therapeutics that may suppress the clinical features of 
preeclampsia. 
 
Hydrogen sulfide releasing molecule rescued maternal outcome in Hmox1+/- 
pregnant mice in a high sFlt-1 environment. 
To evaluate the therapeutic potential of H2S-releasing aspirin, MZe786, in preeclampsia, 
Hmox1+/- mice were injected with Ad-sFlt-1 on day E11.5 and simultaneously given four 
treatment regimens (drug carrier, MZe786, MZe486 or aspirin). Firstly, to prove that 
MZe786 releases H2S, the methylated metabolite of H2S, trimethylsulfonium (TMS) was 
measured in the urine of Hmox1+/- mice by mass spectroscopy. TMS was significantly 
increased in the MZe786 and MZe486 treated animals indicating an increase in the H2S 
pool by the H2S-releasing drugs (Figure 2A). MZe786 significantly reduced MAP in 
Hmox1+/- pregnant mice exposed to high levels of sFlt-1 (Figure 2B). Interestingly, no 
significant changes were seen in MZe486 and aspirin-treated Hmox1+/- mice (Figure 2B). 
Representative H&E staining showed severe glomerular damage in Hmox1+/- pregnant 
mice treated with Ad-sFlt-1 compared to Ad-CMV treatment (Figure 2C). Administration of 
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H2S-releasing molecules rescued glomerular damage. This was quantified using 
randomized single-blind scoring of kidney sections which showed a significant reduction in 
the levels of glomeruli damage in mice administered with MZe786 and MZe486 under high 
sFlt-1 conditions (Figure 2D). Kidney Injury Molecule-1 (KIM-1) is a marker of acute kidney 
injury (37). Overexpression of sFlt-1 significantly increased urinary KIM-1 level in Hmox1+/- 
pregnant mice compared to Ad-CMV treated animals and administration of H2S-releasing 
molecules returned KIM-1 to normal levels (Figure 2E). Surprisingly, mice treated with 
aspirin showed only a slight but not significant reduction in glomerular damage and KIM-1 
levels in the presence of high sFlt-1 (Figure 2C-E).  
Soluble endoglin (sEng) is a marker of endothelial activation and is increased in 
preeclampsia (38, 39). Ad-sFlt-1 injection significantly increased circulatory levels of sEng 
in Hmox1+/- pregnant mice compared to Ad-CMV injected counterparts and concomitant 
administration of MZe786 significantly reduced sEng. However, MZe486 and aspirin did 
not reduce sEng in these mice (Figure 2F). The levels of E-selectin, a circulating adhesion 
molecule were also tested to evaluate endothelial activation in Hmox1+/- pregnant mice 
under a high sFlt-1 environment. Hmox1+/- mice treated with Ad-sFlt-1 increased plasma 
E-selectin while administration of MZe786, MZe486 and Aspirin reduced E-selectin 
(Supplementary Figure S1A). The drugs administered had no interference with sFlt-1 
production in these mice as the circulating level of sFlt-1 measured on day E17.5 
consistently showed a significant increase in Ad-sFlt-1 injected mice (Supplementary 
Figure S1B) and there was no significant change in the circulating levels of VEGF in any of 
the treatment groups (Supplementary Figure S1C). 
 
Hydrogen sulfide releasing molecule rescued fetal outcome in Hmox1+/- pregnant 
mice in a high sFlt-1 environment. 
Jo
urn
al 
Pr
e-p
roo
f
 11
Fetuses with FGR are at risk of poor long-term health outcomes, such as cardiovascular 
and endocrine disease in adulthood (40) and neurological development (41). To evaluate 
the effect of H2S-releasing aspirin, MZe786, on the fetal outcome, fetal loss and fetal 
weights were assessed on E17.5. Figure 3A shows representative images of healthy-
looking uterine horns in Hmox1+/- pregnant mice when treated with H2S-releasing 
molecules under high levels of sFlt-1. Overexpression of sFlt-1 led to 44.4% fetal loss in 
Hmox1+/- mice compared to 26.1% in Ad-CMV injected mice. Administration of MZe786 
and MZe486 significantly reduced the fetal loss to 18.6% and 22.2%, respectively (Figure 
3B). A slight but not significant reduction in the fetal loss was also observed in aspirin-
treated mice (Figure 3B). Administration of MZe786, MZe486 and aspirin decreased FGR 
from 33.3% to 14.23%, 19.2% and 22.2%, respectively (Figure 3C, Supplementary Table 
S2).  
Abnormal development of the placenta has long been associated with abnormal fetal 
outcome (13). The labyrinth zone is made of two layers of multinucleated 
syncytiotrophoblast cells where the exchange of nutrients and waste takes place between 
the mother and the fetus (42). Double-blinded histological analysis of the placental 
sections showed that overexpression of sFlt-1 significantly reduced labyrinth zone area in 
Hmox1+/- pregnant mice compared to Ad-CMV injected mice. Oral administration of 
MZe786 increased labyrinth zone area. No changes were observed in MZe486 or aspirin 
treated mice (Supplementary Figure S2). Interestingly, there were no changes to the 
resistance index of the uterine or the umbilical artery measurements using ultrasound 
following these different treatment regiments (Supplementary Figure S3). The 
Fetal:Placental ratio is a health indicator reflecting the balance between fetal and placental 
growth (43). The ratio was significantly reduced in the high sFlt-1 environment and this 
was rescued by administration of MZe786 in Hmox1+/- mice. No changes in Fetal:Placental 
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ratio were seen in MZe486 or aspirin-treated Hmox1+/- pregnant mice in high sFlt-1 
conditions (Figure 3D).  
 
MZe786 stimulates antioxidant genes in a high sFlt-1 environment in Hmox1+/- 
pregnant mice 
Soluble Flt-1 is reported to exacerbate mitochondrial reactive oxygen species formation 
and mitochondrial membrane potential dissipation in endothelial cell (44, 45). As high sFlt-
1 induced kidney injury, we sought to investigate if low HO-1 and high sFlt-1 compromise 
the expression of antioxidant genes and whether MZe786 or aspirin could rescue this 
damage. Adenoviral overexpression of sFlt-1 in Hmox1+/- pregnant mice significantly 
reduced the transcription of antioxidant defence genes in the kidney; thioredoxin (Txn1) 
(Figure 4A) and glutaredoxin-1 (Glrx) (Figure 4B). Oral administration of MZe786 
significantly restored the transcription of Txn1 and Glrx (Figure 4A and 4B). Peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC1-α), a master regulator of 
metabolism and antioxidant defence system, was also reduced in Hmox1+/- pregnant mice 
injected with Ad-sFlt-1 which was restored by the administration of MZe786 (Figure 4C). 
Accordingly, MZe786 restored the content of mitochondria as measured by the ratio of 
mitochondrial DNA and nuclear DNA (mtDNA/nDNA) (Figure 4D). Aspirin alone did not 
restore the transcription of Txn1 and Glrx and did not improve the mitochondrial 
biogenesis signal or mitochondrial content in the kidney of Hmox1+/- pregnant mice 
injected with Ad-sFlt-1 (Figure 4). These results suggest that MZe786 may regulate the 
content of mitochondria by modulating the transcription and expression of PGC1α.  
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Discussion 
Earlier studies demonstrated that HO-1 is a negative regulator of sFlt-1 (19) and is 
decreased in preeclampsia (18). Overexpression of sFlt-1 leads to high blood pressure, 
kidney damage and fetal growth restriction as previously reported in pregnant rat (46) and 
mice (47). In a low HO-1 environment, the adverse outcomes associated with 
overexpression of sFlt-1 were further aggravated with an increase in blood pressure, 
kidney damage and fetal death. Partial loss of HO-1 alone did not show visible features of 
preeclampsia in these pregnant mice; however, these clinical phenotypes were only 
present and exacerbated when sFlt-1 levels were high. Our data demonstrate that 
preeclampsia arises due to a double hit, a combination of decreased HO-1 activity and 
increased sFlt-1 levels leading to systemic endothelial activation and organ damage.  
The National Institute of Health and Care Excellence’s (NICE) recommends that women at 
high risk of developing preeclampsia should take 75-150mg of aspirin daily from 12 weeks 
of pregnancy until delivery (48). Although aspirin only reduces the risk of preeclampsia by 
15%, it does so without changing the incidence of FGR (8, 49). Furthermore, there is no 
therapeutic available to prevent preeclampsia. The only way to prevent a life-threatening 
seizure developing due to eclampsia, is the premature delivery of the baby with the 
placenta. 
The lack of an effective therapeutic to prevent or treat preeclampsia is responsible for an 
annual global cost burden of GBP 76.6 billion (50). In the preeclamptic model where sFlt-1 
levels are high and HO-1 activity is low, we show that aspirin is unable to prevent 
preeclampsia by inhibiting hypertension or kidney injury or preventing fetal loss. It is known 
for over a decade that H2S and its precursors are potent inducers of HO-1 (51, 52). A 
novel approach to prevent preeclampsia was to develop a chemically modified aspirin. 
MZe786, 2-acetyloxybenzoic acid 4-(3-thioxo-3H-1,2-dithiol5-yl)phenyl ester is a novel 
molecule (also known as ACS14) comprising of an H2S-releasing dithiole-thione moiety 
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(MZe486, also named ADTOH) attached by an ester linkage to aspirin (32). It protects the 
gastric mucosa via its anti-cyclooxygenase activity. It is able to suppress thromboxane 
synthesis, to decrease 8-isoprostane levels and homocysteine levels as well as to 
increase plasma and tissue glutathione (GSH) levels. In addition, MZe786 produces a 
concentration-dependent increase in Hmox1 promoter activity in NIH3T3-HO-1-luc cells 
whereas aspirin had no significant increase on Hmox1 promoter activity in these cells (32). 
It also exerted cardiovascular protection in a buthionine sulfoximine (GSH synthase 
inhibitor) model of metabolic syndrome (53). These effects of MZe786 may help to balance 
the redox system.  
H2S-releasing aspirin, MZe786, successfully reduced blood pressure, kidney damage and 
improved fetal outcome in Hmox1+/- mice under high levels of sFlt-1 in part, by increasing 
the release of H2S as its’ metabolite, TMS, is increased in MZe786 treated group and not 
in the aspirin group. The presence of TMS in the urine is a good indicator of the presence 
of H2S in the kidney and circulation. The potential of MZe786 and MZe486 to release H2S 
in circulation has been previously reported by Giustarini et al., 2010. Administration of 
MZe786 and MZe486 increased Cysteine and GSH levels in many organs, including the 
kidney (54). This is a good indicator of H2S release and MZe786’s ability to modulate thiol 
homeostasis to offer protection and reduce oxidative stress and may explain the inhibitory 
effect of MZe786 on KIM-1 and sEng suppression.  
Our results provide novel insights into the role of HO-1 in modulating the antioxidant gene 
expression and suggest MZe786 protects the renal antioxidant capacity. Our study 
demonstrates that MZe786 improves the renal antioxidant capacity via upregulation of Trx-
1 and Glrx genes transcription. Several mitochondrial dysregulation pathways have been 
associated with endothelial dysfunction including, PGC-1α, a transcriptional coactivator 
linked to mitochondrial biogenesis and antioxidant defense. Overexpression of sFlt-1 
reduced PGC-1α gene transcription and mitochondrial content in Hmox1+/- pregnant mice 
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in comparison to Ad-CMV injected mice. This is in line with our recent publication, which 
demonstrated that overexpression of sFlt-1 reduced transcription of cardiac antioxidant 
genes in non-pregnant Hmox1+/- mice. In addition, sFlt-1 led to inhibition of cardiac 
mitochondrial activity and administration of MZe786 increased antioxidant genes and 
rescued mitochondrial activity by stimulating cardiac mitochondrial biogenesis (33).  These 
studies illustrate that despite the presence of high sFlt-1, MZe786 nullified the effect of 
high sFlt-1 and low HO-1 due to its ability to increase the expression of antioxidant genes. 
 
H2S promotes angiogenesis by upregulation of nitric oxide (NO) (55) and H2S donors 
restore placental angiogenesis in pregnant mice under reduced CSE activity (25). VEGF is 
known to stimulate NO release (56). Interestingly, there was no significant change in the 
circulating levels of VEGF in any of the treatment groups. MZe786 may have an impact on 
the VEGF signalling at a cellular level. H2S is known to stimulate tissue VEGF expression, 
which activates endothelial nitric oxide synthase (eNOS) and suppresses oxidative stress 
(57). MZe786 ameliorate placental structural alteration as indicated by increased labyrinth 
zone in Hmox1+/- mice treated with Ad-sFlt-1. Reduced labyrinth zone is associated with 
FGR; a small labyrinth has reduced transport surface area and thereby limiting the nutrient 
available to the fetus (58, 59). In agreement, we see the highest percentage of growth-
restricted pups in Hmox1+/- mice treated with Ad-sFlt-1 and administration of MZe786 
reduces the population of growth-restricted pups back to normal. Importantly, H2S-
releasing molecules, MZe786 and MZe486 decreased fetal death induced by 
overexpression of sFlt-1 in Hmox1+/- mice. Interestingly. there were no changes in the 
resistance index of the uterine or the umbilical artery measured using ultrasound following 
treatment indicating that alteration in uterine artery hemodynamic are not required for 
preventing preeclampsia or improving fetal outcome. 
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Earlier study showed that inhibition of CSE activity in human placental explants from the 
first trimester (8–12 weeks) of pregnancy caused a decrease in placental growth factor 
(PlGF) production (25). The ratio sFlt-1/PlGF is referred to in human pregnancy as a 
potential indicator of preeclampsia. Unfortunately, this is not the same for mouse models 
as the mouse only expresses PlGF-2 transcript (60) and the protein product is heparin-
bound (61). This means that free PlGF in the murine circulation cannot be detected by 
ELISA to reflect a similar scenario as observed in humans. Furthermore, preeclampsia is 
defined by clinical characteristics. The sFlt-1/PlGF ratio has false positives and false 
negatives, it is used as a rule-out test and not as a rule-in test (62). The improvement in 
the clinical parameters with the MZe786 clearly demonstrates that the pathology of 
preeclampsia is halted due to the given compound. 
In conclusion, overexpression of sFlt-1 in HO-1 compromised pregnant mice exhibit the 
clinical features of preeclampsia with a significant increase in blood pressure, kidney 
damage and fetal growth restriction and fetal loss. All these symptoms were prevented by 
the administration of the H2S-releasing aspirin, MZe786 and this offers a novel therapeutic 
strategy over aspirin and is worthy of clinical exploration. 
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Figure Legends 
Figure 1. High sFlt-1 causes a severe preeclampsia phenotype in Hmox1 haploid 
deficient mice. (A) Mean arterial blood pressure (MAP) measured at E17.5 gestation in 
Hmox1+/+ (Black circles) and Hmox1+/- (black triangle) mice after administration of Ad-CMV 
(control) or Ad-sFlt-1 (1x109 pfu) at E11.5. (B) Serial sections of representative glomeruli 
stained with hematoxylin and eosin (HE). Scale bars, 100 μm. (C) Single-blind analysis of 
glomeruli damage from Hmox1+/+ (Black column) and Hmox1+/- (White column) mice 
treated with Ad-CMV or Ad-sFlt-1. (n=6 Hmox1+/+; n=6 Hmox1+/-). (D) Representative 
images of uterine horn (E17.5) showing overexpression of sFlt-1 leads to fetal death (FD). 
(E) Fetal loss expressed as a percentage of the total pup numbers. (F) Fetal weight 
distribution of pups and 10th percentile pup weight population mark, representing the fetal 
growth restriction in the weight curve from Hmox1+/+ and Hmox1+/- mice treated with Ad-
CMV or Ad-sFlt-1. (n=13 Hmox1+/+; n=14 Hmox1+/-). Results are expressed as 
representative or as mean (±SEM). Analysed by Two-way ANOVA.  
 
Figure 2. MZe786 rescues maternal outcome in Hmox1+/- pregnant mice in a high 
sFlt-1 environment. (A) H2S metabolite, trimethyl sulfonium (TMS) levels measured in 
urine on day E17.5 in Hmox1+/- timed pregnant mice injected Ad-sFlt-1 and treated with 
Carrier (control), MZe786, MZe486 or aspirin. (B) Mean arterial blood pressure (MAP) 
recorded at E17.5 gestation in Hmox1+/- timed pregnant mice injected with Ad-CMV or Ad-
sFlt-1 and treated with MZe786, MZe486 or aspirin. (C) Representative serial sections of 
glomeruli stained with hematoxylin and eosin (H&E). Scale bars, 100 μm. (D) Single-blind 
analysis of glomeruli damage. (E) Urinary kidney injury marker -1 (KIM-1) level. (F) Plasma 
sEng level measured on day E17.5 gestation in Hmox1+/- timed pregnant mice injected 
with Ad-CMV or Ad-sFlt-1 and treated with carrier, MZe786, MZe486 or aspirin (n=11 Ad-
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CMV; n=13 Carrier; n=13 MZe786; n=14 MZe486; n=10 Aspirin group). Results are 
expressed as representative or as mean (±SEM). Analysed by One-way ANOVA. 
 
Figure 3. MZe786 improves fetal outcome in a high sFlt-1 environment in Hmox1+/- 
mice. (A) Representative images of uterine horn (E17.5) showing rescue of fetal death 
(FD) in sFlt-1 induced Hmox1+/- mice by H2S-releasing molecules. (B) Fetal loss 
expressed as a percentage over total pup numbers in Hmox1+/- mice injected with Ad-CMV 
or Ad-sFlt-1 and treated with MZe786, MZe486 or aspirin. (C) Hmox1+/- fetal weight 
distribution and 10th percentile pup weight population mark, representing the fetal growth 
restriction in the weight curve (D) Hmox1+/- Fetal:placental ratio in Hmox1+/- mice injected 
with Ad-CMV or Ad-sFlt-1 and treated with MZe786, MZe486 or aspirin. Results are 
expressed as representative or as mean (±SEM). Analysed by One-way ANOVA. 
 
Figure 4. MZe786 stimulates antioxidant defence in Hmox1+/- mice overexpressing 
sFlt-1. (A) Kidney relative mRNA expression of genes; (B) Txn1, (C) Glrx and (D) PGC1α 
measured by quantitative PCR n Hmox1+/- mice injected with Ad-CMV or Ad-sFlt-1 and 
treated with carrier, MZe786 or aspirin. (E) Mitochondrial content measured as the ratio of 
mtDNA/nDNA in Hmox1+/- mice injected with Ad-CMV or Ad-sFlt-1 and treated with carrier, 
MZe786 or aspirin. Results are expressed as representative or as mean (±SEM). Analysed 
by One-way ANOVA. 
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